Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02319044
Registration number
NCT02319044
Ethics application status
Date submitted
12/12/2014
Date registered
18/12/2014
Date last updated
29/09/2020
Titles & IDs
Public title
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Query!
Scientific title
A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination With Tremelimumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Query!
Secondary ID [1]
0
0
D4193C00003
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Cancer
0
0
0
0
Query!
Head and neck
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - MEDI4736
Treatment: Drugs - Tremelimumab
Treatment: Drugs - MEDI4736 + Tremelimumab
Experimental: MEDI4736 - MEDI4736 monotherapy
Experimental: Tremelimumab - Tremelimumab monotherapy
Experimental: MEDI4736 + Tremelimumab - MEDI4736 + Tremelimumab combination therapy
Treatment: Drugs: MEDI4736
MEDI4736 monotherapy
Treatment: Drugs: Tremelimumab
Tremelimumab monotherapy
Treatment: Drugs: MEDI4736 + Tremelimumab
MEDI4736 + Tremelimumab combination therapy
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Objective Response Rate at 6 Months
Query!
Assessment method [1]
0
0
Objective response rate, primary analysis, based on BICR assessments according to RECIST v1.1. The number (%) of patients with a response excludes unconfirmed responses
Query!
Timepoint [1]
0
0
After 6 months
Query!
Primary outcome [2]
0
0
Objective Response Rate at 12 Months
Query!
Assessment method [2]
0
0
Objective response rate (per RECIST 1.1 as assessed by blinded independent central review [BICR]) is defined as the number (%) of patients with a confirmed complete response or confirmed partial response and will be based on all treated patients who are PD-L1-positive with measurable disease at baseline per BICR. Response Evaluation Criteria in Solid Tumors [RECIST] 1.1. criteria are: Complete response [CR] = disappearance of all target lesions since baseline; and partial response [PR] = at least a 30% decrease in the sum of the diameters of target lesions.
Query!
Timepoint [2]
0
0
After 12 months
Query!
Secondary outcome [1]
0
0
Best Objective Response
Query!
Assessment method [1]
0
0
The best response a patient has had during their time in the study
Query!
Timepoint [1]
0
0
After 12 months
Query!
Secondary outcome [2]
0
0
Duration of Response - Participants Remaining in Response
Query!
Assessment method [2]
0
0
Participants remaining in response - based on BICR assessments according to RECIST v1.1. An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off.
Query!
Timepoint [2]
0
0
After 12 months
Query!
Secondary outcome [3]
0
0
Time to Response
Query!
Assessment method [3]
0
0
Time to response in patients with objective response based on BICR assessments according to RECIST 1.1
Query!
Timepoint [3]
0
0
After 12 months
Query!
Secondary outcome [4]
0
0
Time to Onset of Response From First Dose
Query!
Assessment method [4]
0
0
Time to onset of response in patients with objective response based on BICR assessments according to RECIST 1.1
Query!
Timepoint [4]
0
0
After 12 months
Query!
Secondary outcome [5]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [5]
0
0
Disease control rate (DCR) at 6 months based on BICR assessments according to RECIST v1.1. DCR at 6 months was evaluated using 2 different approaches to the length of stable disease (SD). -Method 1: Patients who had a best objective response of complete response (CR) or partial response (PR) within 24 weeks or had demonstrated SD for a minimum interval of 24 weeks following randomization. -Method 2: Patients who had a best objective response of CR or PR in the first 24 weeks or who had demonstrated SD for a minimum interval of 16 weeks following randomization.
Query!
Timepoint [5]
0
0
After 6 months
Query!
Secondary outcome [6]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [6]
0
0
Disease control rate (DCR) at 12 months based on BICR assessments according to RECIST v1.1. DCR at 6 months was evaluated using 2 different approaches to the length of stable disease (SD). -Method 1: Patients who had a best objective response of complete response (CR) or partial response (PR) within 24 weeks or had demonstrated SD for a minimum interval of 24 weeks following randomization. -Method 2: Patients who had a best objective response of CR or PR in the first 24 weeks or who had demonstrated SD for a minimum interval of 16 weeks following randomization.
Query!
Timepoint [6]
0
0
After 12 months
Query!
Secondary outcome [7]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [7]
0
0
Progression status at 6 months based on BICR assessments according to RECIST v1.1 at time of Progression Free Survival (PFS) analysis. Progression was defined as the time from the data of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. -Target Lesions, Non Target Lesions and New Lesions are not necessarily mutually exclusive categories. -Progression death refers to death in the absence of RECIST 1.1 progression.
Query!
Timepoint [7]
0
0
After 6 months
Query!
Secondary outcome [8]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [8]
0
0
Progression status at 12 months based on BICR assessments according to RECIST v1.1 at time of Progression Free Survival (PFS) analysis. Progression was defined as the time from the data of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. -Target Lesions, Non Target Lesions and New Lesions are not necessarily mutually exclusive categories. -Progression death refers to death in the absence of RECIST 1.1 progression.
Query!
Timepoint [8]
0
0
After 12 months
Query!
Secondary outcome [9]
0
0
Overall Survival
Query!
Assessment method [9]
0
0
Survival status at time of overall survival analysis. 'Still in survival follow-up' includes patients known to be alive at data cut-off. 'Terminated prior to death' includes patients with unknown survival status or patients who were lost to follow-up.
Query!
Timepoint [9]
0
0
After 12 months
Query!
Secondary outcome [10]
0
0
Quality of Life
Query!
Assessment method [10]
0
0
Improvement in quality of life was assessed using European Organisation for Research and Treatment of Cancer (EORTC) questionnaires: -The impact of treatment on Health-Related Quality of Life, functioning, and symptoms was evaluated using the EORTC QLQ-C30 v3. -Head and neck cancer-specific symptoms were evaluated using the EORTC QLQ-H&N35. The symptom and QoL/function improvement rate was defined as the number (%) of patients with 2 consecutive assessments at least 14 days apart that showed a clinically meaningful improvement (a decrease from baseline score =10 or EORTC QLQ-C30 scales) in that symptom/function from baseline. For QLQ-H&N35A a minimum clinically meaningful change was defined as a change in the score from baseline of >10 for scales/items
Query!
Timepoint [10]
0
0
After 12 months
Query!
Secondary outcome [11]
0
0
Duration of Response
Query!
Assessment method [11]
0
0
Duration of objective response in patients with objective response based on BICR assessments according to RECIST v1.1. Duration of response was the time from the first documentation of Complete response/Partial response (which was subsequently confirmed) until the date of progression, death, or the last evaluable RECIST assessment for patients that did not progress. An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off (per RECIST v1.1 as assessed by BICR).
Query!
Timepoint [11]
0
0
After 12 months
Query!
Eligibility
Key inclusion criteria
- Age =18 years;
- Written informed consent obtained from the patient/legal representative;
- Histologically confirmed recurrent or metastatic SCCHN; tumor progression or
recurrence during or after treatment with only 1 systemic palliative regimen for
recurrent or metastatic disease that must have contained a platinum agent; Patients
who have only received chemo-radiation with curative intent for treatment of their
locally advanced disease or recurrent disease are not eligible. Patients who received
concurrent chemo-radiation as part of treatment of their recurrent disease are also
not eligible.
- Written consent to provide newly acquired tumor tissue (preferred) or archival tissue
for the purpose of establishing PD-L1 status.
- Confirmed PD-L1-negative SCCHN by Ventana SP263;
- WHO/ECOG performance status of 0 or 1;
- At least 1 measurable lesion at baseline;
- No prior exposure to immune-mediated therapy;
- Adequate organ and marrow function; Evidence of post-menopausal status or negative
urinary or serum pregnancy test.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
96
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Histologically confirmed squamous cell carcinoma of any other primary anatomic
location in the head and neck;
- Received more than 1 regimen for recurrent or metastatic disease
- Any concurrent chemotherapy, Investigational Product, biologic, or hormonal therapy
for cancer treatment;
- Receipt of any investigational anticancer therapy within 28 days or 5 half-lives;
- Receipt of last dose of an approved (marketed) anticancer therapy (chemotherapy,
targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose
of study treatment;
- Major surgical procedure within 28 days prior to the first dose of Investigational
Product;
- Any unresolved toxicity NCI CTCAE Grade =2 from previous anticancer therapy with the
exception of alopecia, vitiligo, and the laboratory values defined in the inclusion
criterion;
- Current or prior use of immunosuppressive medication within 14 days before the first
dose of their assigned Investigational Product;
- History of allogeneic organ transplantation;
- Active or prior documented autoimmune or inflammatory disorders;
- Uncontrolled intercurrent illness;
- another primary malignancy
- Patients with history of brain metastases, spinal cord compression, or a history of
leptomeningeal carcinomatosis;
- History of active primary immunodeficiency;
- Known history of previous tuberculosis;
- Active infection including hepatitis B, hepatitis C or human immunodeficiency virus
(HIV);
- Receipt of live, attenuated vaccine within 30 days prior to the first dose of
Investigational Product;
- Pregnant or breast-feeding female patients;
- Mean QT interval corrected for heart rate (QTc) =470 ms calculated from 3
electrocardiograms (ECGs) using Fridericia's Correction
- Known allergy or hypersensitivity to Investigational Product.
- Any condition that, in the opinion of the Investigator, would interfere with
evaluation of the IP or interpretation of patient safety or study results
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
15/04/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
6/07/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
267
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Adelaide
Query!
Recruitment hospital [2]
0
0
Research Site - Darlinghurst
Query!
Recruitment hospital [3]
0
0
Research Site - Tweed Heads
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [3]
0
0
2485 - Tweed Heads
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Minnesota
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Missouri
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Hampshire
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New York
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
North Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Oregon
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Pennsylvania
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
South Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Tennessee
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Texas
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
West Virginia
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Wisconsin
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Brussels
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Charleroi
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Kortrijk
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Leuven
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Namur
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Alberta
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
New Brunswick
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Ontario
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Quebec
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Olomouc
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Zlin
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Angers
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Bordeaux
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Brest
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Dijon
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Le Mans
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Lille cedex
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Lorient cedex
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Lyon Cedex 08
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Montpellier
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Nice
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Rouen
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Saint Brieuc
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
St Grégoire
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Strasbourg Cedex
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Toulouse Cedex 9
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Villejuif Cedex
Query!
Country [52]
0
0
Georgia
Query!
State/province [52]
0
0
Batumi
Query!
Country [53]
0
0
Georgia
Query!
State/province [53]
0
0
Tbilisi
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Berlin
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Halle
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Hannover
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Heidelberg
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Leipzig
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
München
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Budapest
Query!
Country [61]
0
0
Hungary
Query!
State/province [61]
0
0
Gyula
Query!
Country [62]
0
0
Hungary
Query!
State/province [62]
0
0
Györ
Query!
Country [63]
0
0
Hungary
Query!
State/province [63]
0
0
Kecskemét
Query!
Country [64]
0
0
Hungary
Query!
State/province [64]
0
0
Miskolc
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Zalaegerszeg
Query!
Country [66]
0
0
Israel
Query!
State/province [66]
0
0
Haifa
Query!
Country [67]
0
0
Israel
Query!
State/province [67]
0
0
Petach-Tikva
Query!
Country [68]
0
0
Israel
Query!
State/province [68]
0
0
Tel Hashomer
Query!
Country [69]
0
0
Korea, Republic of
Query!
State/province [69]
0
0
Daegu
Query!
Country [70]
0
0
Korea, Republic of
Query!
State/province [70]
0
0
Goyang-si
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Suwon
Query!
Country [72]
0
0
Malaysia
Query!
State/province [72]
0
0
Kuala Lumpur
Query!
Country [73]
0
0
Malaysia
Query!
State/province [73]
0
0
Kuching
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Barakaldo
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Barcelona
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Gerona
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Granada
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Jaén
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Madrid
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Malaga
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Marbella (Málaga)
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Valencia
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Zaragoza
Query!
Country [84]
0
0
Taiwan
Query!
State/province [84]
0
0
Taipei
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Aberdeen
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Birmingham
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Glasgow
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
London
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Manchester
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Wirral
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
PRA Health Sciences
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine the efficacy and safety of investigational medical
products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab
combination therapy) in the treatment of patients with recurrent or metastatic carcinoma of
the head and neck who have progressed during or after treatment with a platinum containing
regimen for recurrent/metastatic disease.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02319044
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Magdalena Wrona
Query!
Address
0
0
Medical Scientist AstraZeneca
[email protected]
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02319044
Download to PDF